Other
Leptomeningeal Disease
0
Pipeline Programs↗
3
Active Trials↗
1
Companies Involved↗
Leptomeningeal Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Alireza Mansouri.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Terminated2 · 29%
Not yet recruiting2 · 29%
Completed1 · 14%
Withdrawn1 · 14%
Recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
ctDNA-Guided Intraventricular Therapy Trial: A Prospective Study in Patients With Malignant Gliomas or Brain Metastases From Non-Small Cell Lung Cancer and Breast Cancer
Not yet recruiting·—·Preclinical·NCT07689721·77 enrolled
Pembrolizumab in Patients With Leptomeningeal Disease
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03091478·13 enrolled
Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease
Withdrawn·—·N/A·NCT01438021
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)